Steve Potts

CEO at Breakthru Medicine

Speaker

Steve Potts is Co-Founder and CEO of Breakthru Medicine, a stealth IND-stage company that has raised $45M in a Series A with opportunity for several more investors to complete the round. The Breakthru team has been involved in 12 successful approved cancer drugs.

He founded the multi-armed immunotherapy company OncoMyx in 2018 and raised $75M in venture funding. Previously, he was an executive at Ignyta, which was acquired by Roche/Genentech for $1.7B, where he led the global operation testing over 20,000 patients in an oncology basket trial for entrectinib in 8 European countries, and 15 worldwide. He has been a founder and executive in multiple successful startups and exits in the oncology area, including 3 exits with over 12x returns to investors. He testified in Congress in 2023 regarding the investor damage the Inflation Reduction Act caused with the 'small molecule penalty'. His survey of over 100 American biotech venture capital firms on the impact of the IRA on NDA-path drug development has been widely cited in policy discussions on drug pricing.